查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2016953

血管支架市場：依產品類型、材料、輸送系統、應用和最終用戶分類－2026-2032年全球市場預測

Vascular Stent Market by Product Type, Material, Delivery System, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，血管支架市場價值將達到 114.9 億美元，到 2026 年將成長至 120.9 億美元，到 2032 年將達到 167.3 億美元，複合年成長率為 5.51%。

主要市場統計數據
基準年 2025 114.9億美元
預計年份：2026年 120.9億美元
預測年份 2032 167.3億美元
複合年成長率 (%) 5.51%

對血管支架市場進行概述，重點在於臨床因素、材料和輸送技術的創新，以及對醫療領導者的影響。

血管支架市場正進入一個臨床需求、材料科學和輸送工程相互交融的階段，推動整個治療流程的快速變革。血管成形術和支架置入術長期以來一直是冠狀動脈和周邊血管疾病的主要治療方法，如今，旨在提高生物相容性、降低血管再阻塞和簡化術者工作流程的器械級創新正在重新定義這些技術。同時，患者族群結構的變化以及對價值醫療的日益重視，正迫使醫療系統從長期療效、報銷影響和整體醫療成本等方面仔細審視器械的性能。

從材料突破到微創輸送技術的進步，再到不斷變化的法規，一場重大變革正在重塑血管支架的發展。

血管支架領域正在發生一系列變革性變化，這些變化共同重塑了器械設計、臨床實踐和商業化的路徑。材料科學的進步，包括可生物分解聚合物的成熟和金屬合金的改進，使得器械能夠與血管組織具有更好的動態相容性，並以可控的方式分解或整合到組織中，從而解決了長期以來人們對異物長期存在的擔憂。同時，藥物釋放型平台和表面工程技術的改進降低了血管再阻塞的風險，並將適應症擴展到更複雜的病變。

評估美國於 2025 年實施的關稅對血管支架供應鏈、採購慣例、製造營運和籌資策略的累積影響。

美國於2025年實施的關稅為血管支架產業的相關人員帶來了新的物流和採購計畫的不確定性。短期內，關稅改變了進口零件和成品的相對成本結構，迫使製造商修改其採購政策和與供應商的合約。除了簡單的進口關稅計算之外，這項政策變化還引發了更廣泛的戰略應對措施。各公司重新評估了生產地點，實現了供應商多元化，並加快了近岸外包的討論，以降低貿易政策波動帶來的風險。

詳細的細分分析揭示了產品類型、材料成分、給藥方法、臨床應用和最終用戶環境如何決定設備策略。

細分市場層面的趨勢揭示了產品類型、材料成分、輸送方式、臨床應用和終端用戶環境如何共同影響血管支架領域的研發重點和路徑。依產品類型分為球囊擴張型和自動擴張型支架的器械，其設計重點仍存在差異。球囊擴張型支架優先考慮在病變部位提供精確的徑向支撐力和支架形成，而自擴張式支架則側重於與周圍解剖結構的貼合性以及承受長期向外的外力。材料的選擇進一步強化了這些功能上的權衡。採用先進合金的金屬支架具有成熟的徑向支撐力和滲透性，而聚合物支架（分為可生物分解聚合物和不可生物分解聚合物）則有利於臨時支架的形成和降低長期異物負荷。

美洲、歐洲、中東和非洲以及亞太市場的臨床引入、監管途徑和供應鏈策略的區域展望。

區域趨勢對血管支架技術的研發、監管和應用有顯著影響，既帶來了區域性的機遇，也存在著區域性的限制因素。在美洲，先進的臨床基礎設施、集中的介入支架中心以及不斷完善的醫療保險報銷機制共同創造了一個重視可靠臨床證據和上市後療效追蹤的市場環境。因此，該地區的器材上市通常會透過強調隨機對照試驗和真實世界數據（REW）來加速臨床醫生的採納和醫保機構的認可。

血管支架產業的競爭趨勢與策略定位：聚焦創新、夥伴關係、卓越製造與商業化策略

主要血管支架開發商之間的競爭格局呈現出兩極分化的特點：既注重漸進式技術改進，也注重顛覆性平台創新。老牌公司利用規模經濟、成熟的臨床關係和豐富的上市後數據來維持市場佔有率並爭取有利的採購條款。同時，小規模、反應更敏捷的新興參與企業則專注於細分市場差異化，例如新型可生物分解聚合物配方、獨特的表面化學處理或簡化的給藥機制，以期在臨床和商業領域站穩腳跟。這些企業之間的合作通常以授權協議、共同開發夥伴關係和區域分銷協議的形式出現，從而能夠在控制開發風險的同時，快速擴大有前景的技術規模。

為產業領導者提供切實可行的建議，以增強研發協調性、供應鏈韌性、監管參與度和商業化效率。

行業領導者可以採取切實措施，將洞察轉化為永續的競爭優勢，並改善患者療效。首先，將研發重點與具有臨床意義的終點和醫療保健系統價值指標結合，有助於促進醫保報銷談判和臨床醫生採納。投資於上市後證據生成和真實世界數據收集，能夠支持療效聲明，並有助於將其納入臨床實踐指南。其次，必須將供應鏈韌性作為策略重點。雙重採購、庫存最佳化和區域生產方案能夠快速回應臨床需求，同時降低政策變化和物流中斷帶來的風險。

綜合調查方法，結合專家訪談、第二手資料審查、細分分析和情境規劃，確保獲得穩健而實用的見解。

本分析的研究途徑融合了質性專家對話、系統性二手研究以及資料檢驗，從而得出可靠且令人信服的見解。主要資訊來源是對介入性心臟病專家、血管外科醫生、採購經理和法規事務專家的結構化訪談，並輔以器械工程師和製造企業高管的見解。這些觀點有助於我們從不同醫療機構的背景出發，理解臨床實務模式、器材性能優先順序以及採購考量。

摘要強調，技術創新、監管壓力和供應鏈策略的交匯將塑造血管支架的未來。

總之，血管支架領域正處於一個十字路口，材料創新、輸送系統改進、監管預期和政策轉變交織在一起，既帶來了挑戰，也帶來了機會。諸如可生物分解聚合物、增強藥物釋放型技術和低輪廓輸送系統等技術進步，正在拓展冠狀動脈疾病、胃腸道疾病和周邊動脈疾病的臨床治療手段，同時也對證據產生和生命週期管理提出了新的考量。政策趨勢和貿易措施進一步凸顯了供應鏈策略的重要性，促使各組織在不犧牲臨床或品質標準的前提下，追求韌性和區域協同效應。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 血管支架市場：依產品類型分類

  • 球囊擴張型支架
  • 自動擴張型支架

第9章 血管支架市場：依材料分類

  • 金屬支架
  • 聚合物支架
    • 可生物分解聚合物
    • 不可生物分解聚合物

第10章 血管支架市場（依輸送系統分類）

  • 裸金屬支架
  • 覆膜支架
  • 藥物釋放型支架

第11章 血管支架市場：依應用領域分類

  • 冠狀動脈疾病
  • 消化系統疾病
  • 周邊動脈疾病
    • 下肢
    • 上肢

第12章 血管支架市場：依最終用戶分類

  • 門診手術中心
  • 心臟中心
  • 醫院

第13章 血管支架市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 血管支架市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 血管支架市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國血管支架市場

第17章：中國血管支架市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Amaranth Medical, Inc.
  • Artivion Inc.
  • B. Braun SE
  • Becton, Dickinson and Company
  • Biotronik SE & Co. KG
  • Blue Sail Medical Co., Ltd
  • Boston Scientific Corporation
  • Cardinal Health, Inc.
  • Cook Group Incorporated
  • Elixir Medical Corporation
  • Endologix LLC
  • iVascular, SLU
  • Kaneka Corporation
  • Kyoto Medical Planning Co., Ltd.
  • Lepu Medical Technology（Beijing）Co.,Ltd.
  • Lombard Medical Ltd.
  • Medtronic PLC
  • Meril Life Sciences Pvt. Ltd
  • Microport Scientific Corporation
  • Otsuka Medical Devices Co., Ltd.
  • Purple MicroPort Cardiovascular Pvt. Ltd
  • Sahajanand Medical Technologies Limited
  • Stryker Corporation
  • Terumo Corporation
  • Translumina GmbH
  • WL Gore & Associates, Inc.
Product Code: MRR-034B5003037F

The Vascular Stent Market was valued at USD 11.49 billion in 2025 and is projected to grow to USD 12.09 billion in 2026, with a CAGR of 5.51%, reaching USD 16.73 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 11.49 billion
Estimated Year [2026] USD 12.09 billion
Forecast Year [2032] USD 16.73 billion
CAGR (%) 5.51%

Executive overview of the vascular stent landscape emphasizing clinical drivers, material and delivery innovations, and implications for healthcare leaders

The vascular stent landscape has entered a phase where clinical necessity, material science, and delivery engineering intersect to drive rapid change across care pathways. Angioplasty and stenting procedures, long established as core interventions for coronary and peripheral vascular disease, are being redefined by device-level innovation that targets improved biocompatibility, reduced restenosis, and simpler operator workflows. At the same time, evolving patient demographics and growing emphasis on value-based care are prompting health systems to scrutinize device performance across long-term outcomes, reimbursement impact, and total cost of care.

Clinicians and hospital administrators increasingly expect devices that not only meet acute procedural needs but also integrate with modern imaging, reduce downstream complications, and enable ambulatory delivery where appropriate. Consequently, manufacturers are balancing engineering advances with regulatory requirements and procurement realities, while payers and policy-makers assess how new technologies fit into existing coverage frameworks. This confluence of clinical demand, technological progress, and economic evaluation sets the stage for nuanced strategic decision-making, where commercialization plays out at the intersection of evidence generation, supply chain resilience, and stakeholder engagement.

As stakeholders evaluate the next generation of vascular stents, understanding the interplay between materials, device architecture, delivery systems, application-specific performance, and end-user settings becomes essential. This executive analysis synthesizes those dimensions to highlight actionable insights for product development, clinical adoption, and market access strategies that are responsive to current and near-term healthcare imperatives.

Major transformative shifts reshaping vascular stent development from materials breakthroughs to minimally invasive delivery advances and regulatory evolution

The vascular stent environment is experiencing a series of transformative shifts that together are redefining device design, clinical practice, and commercialization pathways. Advances in material science, including the maturation of biodegradable polymers and refined metallic alloys, are enabling devices that better match vascular biomechanics and degrade or integrate in a controlled manner, thereby addressing long-standing concerns about chronic foreign body presence. Concurrently, enhancements in drug-eluting platforms and surface engineering are reducing restenosis risk and expanding indications into more complex lesions.

On the procedural front, delivery systems are becoming more sophisticated, with profiles optimized for tortuous anatomy and mechanisms that improve deployment precision. These engineering changes are accompanied by imaging and intraprocedural diagnostics that allow personalized device selection and positioning, which in turn influence clinical outcomes and reimbursement narratives. Importantly, regulatory frameworks are also evolving; authorities are placing greater emphasis on post-market evidence and real-world performance metrics, which affects product launch strategies and lifecycle management.

Economic and operational forces are equally consequential. Health systems are emphasizing comparative effectiveness and total cost of care, prompting device manufacturers to demonstrate not only clinical efficacy but also downstream value. Finally, patient expectations and demographics-particularly aging populations with comorbidities-are pushing clinicians toward devices that balance durable performance with reduced procedural risk. Taken together, these shifts require manufacturers, clinicians, and payers to collaborate more intensively on evidence generation, adoption pathways, and reimbursement alignment to realize the full potential of new vascular stent innovations.

Assessment of the cumulative effects of United States tariffs enacted in 2025 on vascular stent supply chains, procurement practices, manufacturing operations, and sourcing strategies

The introduction of United States tariffs in 2025 introduced a new variable into the logistics and procurement calculus for vascular stent stakeholders. In the immediate term, tariffs altered the relative cost structure of imported components and finished devices, compelling manufacturers to reassess sourcing decisions and supplier agreements. Beyond the arithmetic of import duties, the policy change catalyzed broader strategic responses: firms re-examined production footprints, engaged in supplier diversification, and accelerated discussions about nearshoring to mitigate exposure to trade policy volatility.

Procurement teams within hospitals, cardiac centers, and ambulatory surgical settings responded by revising contracting strategies, emphasizing longer-term agreements that offered price certainty and supply assurances. These shifts required negotiation of terms that balanced cost containment with continuity of clinical supply, while clinical teams worked to preserve device preference pathways and procedural quality. Meanwhile, regulatory compliance and quality oversight remained central; relocating or altering manufacturing processes demanded rigorous validation to ensure product equivalence and to satisfy both domestic and international regulators.

Over time, the tariffs also influenced partnership models and capital allocation decisions. Some manufacturers invested in regional manufacturing capabilities to serve specific geographic markets more efficiently, while others deepened relationships with local suppliers to shorten lead times and reduce inventory risk. Importantly, the cumulative effect was not only transactional but strategic: organizations recalibrated their approach to resilience, placing greater emphasis on scenario planning, dual sourcing, and supply chain transparency to withstand future policy shifts and sustain patient access to critical vascular therapies.

In-depth segmentation analysis revealing how product type, material composition, delivery modality, clinical application, and end-user settings determine device strategy

Segment-level dynamics reveal how product type, material composition, delivery modality, clinical application, and end-user setting collectively shape development priorities and adoption pathways in the vascular stent domain. Devices classified by product type as balloon-expandable stents and self-expanding stents continue to diverge in engineering emphasis; balloon-expandable platforms prioritize precise radial force and lesion scaffolding, whereas self-expanding designs focus on conformability and chronic outward force for peripheral anatomy. Material choices reinforce these functional trade-offs: metallic stents, leveraging advanced alloys, deliver proven radial strength and radiopacity, while polymeric stents-split into biodegradable polymers and non-biodegradable polymers-open pathways for transient scaffolding and reduced long-term foreign body burden.

Delivery systems further differentiate value propositions. Traditional bare metal stents are contrasted with covered stents that provide barrier functions, and drug-eluting stents that combine mechanical support with pharmacologic prevention of neointimal hyperplasia. Application-specific requirements also drive segmentation: coronary artery disease demands utmost precision and restenosis control, gastrointestinal disease introduces unique luminal dynamics and tissue interactions, and peripheral artery disease-encompassing lower extremities and upper extremities-requires attention to long segment flexibility, compression resistance, and fatigue durability. Finally, end-user settings such as ambulatory surgical centers, cardiac centers, and hospitals influence device specifications and commercialization tactics; devices adopted in ambulatory contexts often need streamlined workflows and rapid recovery profiles, whereas hospital and cardiac center use cases may prioritize advanced feature sets and integration with hybrid operating suites.

Understanding how these segmentation dimensions interrelate is essential for designing clinical trials, prioritizing R&D investment, and tailoring market access approaches that reflect the nuanced requirements of distinct procedural contexts and care delivery models.

Regional perspectives on clinical adoption, regulatory pathways, and supply chain strategy across the Americas, Europe Middle East & Africa, and Asia-Pacific markets

Regional dynamics exert a powerful influence on how vascular stent technologies are developed, regulated, and adopted, producing geography-specific opportunities and constraints. In the Americas, a combination of advanced clinical infrastructure, concentrated centers of interventional expertise, and evolving reimbursement frameworks creates a market environment that rewards robust clinical evidence and post-market outcome tracking. Consequently, device launches in this region typically emphasize randomized and real-world evidence to accelerate clinician adoption and payer acceptance.

Across Europe, Middle East & Africa, regulatory harmonization efforts and diverse health system financing models create a complex mosaic for market entry. Variations in procurement policy and health technology assessment processes mean that manufacturers must adapt value propositions and evidence packages to satisfy regional and national decision-makers. In contrast, the Asia-Pacific region presents a mix of high-volume procedural demand and rapid adoption of new delivery models, with an increasing emphasis on localized manufacturing capabilities and regulatory pathways that can expedite conditional approvals while requiring contextually relevant clinical data. Taken together, these regional distinctions shape strategic priorities for manufacturing location, clinical evidence generation, and commercial partnerships, making geography a key determinant of product lifecycles and go-to-market planning.

Ultimately, a nuanced regional approach that aligns clinical evidence strategies, regulatory engagement, and supply chain architecture with local system expectations enhances the likelihood of successful adoption and sustained utilization across diverse health markets.

Competitive dynamics and strategic positioning across the vascular stent industry highlighting innovation, partnerships, manufacturing excellence, and commercialization tactics

Competitive dynamics among leading vascular stent developers are characterized by a dual emphasis on incremental engineering refinement and disruptive platform innovation. Companies with deep manufacturing heritage leverage scale, established clinical relationships, and extensive post-market datasets to defend share and negotiate favorable procurement terms. Simultaneously, smaller and more agile entrants focus on niche differentiation-such as novel biodegradable polymer formulations, unique surface chemistries, or simplified delivery mechanisms-to create clinical and commercial footholds. Collaboration between these cohorts often takes the form of licensing agreements, co-development partnerships, and localized distribution deals that enable rapid scaling of promising technologies while managing development risk.

Investment flows are increasingly directed toward technologies that demonstrate clear procedural efficiency gains, improved long-term outcomes, or strong compatibility with imaging modalities. Intellectual property portfolios around drug elution kinetics, bioresorbable matrix design, and low-profile delivery catheters remain central competitive assets. Moreover, recent trends show heightened attention to quality systems and supply chain traceability, with companies investing in serialization, manufacturing analytics, and supplier auditing to meet regulatory expectations and customer demands. Strategic M&A activity and selective partnerships are also shaping the competitive landscape, allowing firms to expand clinical reach, augment technological capabilities, or enter new geographic markets with reduced time-to-adoption.

For industry participants, the interplay of scale, innovation focus, regulatory compliance, and partnership strategy determines not only short-term competitive positioning but also long-term sustainability in a market that prizes both clinical excellence and operational resilience.

Actionable recommendations for industry leaders to strengthen R&D alignment, supply chain resilience, regulatory engagement, and commercialization effectiveness

Industry leaders can take concrete steps to translate insight into durable competitive advantage and improved patient outcomes. First, aligning R&D priorities with clinically meaningful endpoints and health system value metrics will strengthen reimbursement discussions and clinician adoption. Investing in post-market evidence generation and real-world data collection will validate performance claims and facilitate inclusion in care pathways. Second, supply chain resilience should be elevated to a strategic priority: dual sourcing, inventory optimization, and regional manufacturing options can reduce exposure to policy shifts and logistic disruptions while enabling faster response to clinical demand.

Third, developing clear commercialization pathways tailored to end-user settings-such as ambulatory surgical centers, cardiac centers, and hospitals-will improve uptake by matching device attributes to procedural requirements and workflow realities. Fourth, engaging with regulators early and proactively on study design and post-market surveillance reduces approval risk and accelerates market entry. Fifth, consider partnership models that combine technological differentiation with distribution strength; co-development and licensing can speed time-to-market and allow resource sharing for evidence generation. Finally, invest in clinician training and adoption programs that emphasize procedural efficiency and outcomes tracking, as hands-on familiarity remains a key determinant of long-term device preference.

Taken together, these actions create a cohesive strategy that balances technological leadership with commercial pragmatism and operational robustness, positioning organizations to succeed in a rapidly evolving vascular stent environment.

Comprehensive research methodology combining expert interviews, secondary evidence curation, segmentation analysis, and scenario planning to ensure robust actionable insights

The research approach underpinning this analysis integrates qualitative expert engagement with systematic secondary research and data triangulation to produce robust, defensible insights. Primary inputs included structured interviews with interventional cardiologists, vascular surgeons, procurement leaders, and regulatory affairs specialists, complemented by device engineers and manufacturing operations executives. These perspectives provided contextual understanding of clinical practice patterns, device performance priorities, and procurement considerations across care settings.

Secondary research was used to map regulatory frameworks, device approval pathways, and published clinical evidence, with careful curation to avoid reliance on unverified sources. Quantitative inputs were synthesized where available to support thematic conclusions, but the emphasis remained on triangulating multiple data sources to validate observations. Analytical methods included cross-segmentation analysis to understand how product type, material, delivery system, application, and end-user interact, and scenario analysis to explore the implications of policy shifts such as tariffs. Quality assurance procedures included source verification, expert review, and iterative refinement of findings to ensure clarity, relevance, and practical applicability for decision-makers.

Ethical considerations, confidentiality of expert contributions, and adherence to applicable research standards guided the methodology throughout, ensuring that conclusions are evidence-based and oriented toward strategic utility for industry stakeholders.

Concluding synthesis emphasizing the intersection of technological innovation, regulatory pressure, and supply chain strategy shaping the vascular stent future

In conclusion, the vascular stent sector stands at an inflection point where material innovation, delivery system refinement, regulatory expectations, and policy shifts intersect to create both challenges and opportunities. Technological advances such as biodegradable polymers, enhanced drug-elution technologies, and low-profile delivery systems are expanding the clinical toolkit for treating coronary, gastrointestinal, and peripheral arterial disease, while simultaneously raising new considerations for evidence generation and lifecycle management. Policy developments and trade measures have amplified the importance of supply chain strategy, prompting organizations to pursue resilience and regional alignment without sacrificing clinical or quality standards.

Strategically, manufacturers and healthcare providers must balance the imperatives of clinical performance, economic value, and operational reliability. Success will hinge on integrated approaches that combine rigorous clinical evidence with adaptive manufacturing and procurement models, targeted commercialization strategies for varied end-user environments, and proactive regulatory engagement. By focusing investments where clinical benefit and system value converge, industry participants can accelerate adoption, improve patient outcomes, and create sustainable commercial models. The themes explored in this analysis provide a roadmap for executives to prioritize initiatives, manage risk, and capture opportunities in the evolving vascular stent landscape.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Vascular Stent Market, by Product Type

  • 8.1. Balloon-Expandable Stents
  • 8.2. Self-Expanding Stents

9. Vascular Stent Market, by Material

  • 9.1. Metallic Stents
  • 9.2. Polymeric Stents
    • 9.2.1. Biodegradable Polymers
    • 9.2.2. Non-Biodegradable Polymers

10. Vascular Stent Market, by Delivery System

  • 10.1. Bare Metal Stents
  • 10.2. Covered Stents
  • 10.3. Drug Eluting Stents

11. Vascular Stent Market, by Application

  • 11.1. Coronary Artery Disease
  • 11.2. Gastrointestinal Disease
  • 11.3. Peripheral Artery Disease
    • 11.3.1. Lower Extremities
    • 11.3.2. Upper Extremities

12. Vascular Stent Market, by End User

  • 12.1. Ambulatory Surgical Centers
  • 12.2. Cardiac Centers
  • 12.3. Hospitals

13. Vascular Stent Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Vascular Stent Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Vascular Stent Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Vascular Stent Market

17. China Vascular Stent Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. Amaranth Medical, Inc.
  • 18.7. Artivion Inc.
  • 18.8. B. Braun SE
  • 18.9. Becton, Dickinson and Company
  • 18.10. Biotronik SE & Co. KG
  • 18.11. Blue Sail Medical Co., Ltd
  • 18.12. Boston Scientific Corporation
  • 18.13. Cardinal Health, Inc.
  • 18.14. Cook Group Incorporated
  • 18.15. Elixir Medical Corporation
  • 18.16. Endologix LLC
  • 18.17. iVascular, S.L.U
  • 18.18. Kaneka Corporation
  • 18.19. Kyoto Medical Planning Co., Ltd.
  • 18.20. Lepu Medical Technology(Beijing)Co.,Ltd.
  • 18.21. Lombard Medical Ltd.
  • 18.22. Medtronic PLC
  • 18.23. Meril Life Sciences Pvt. Ltd
  • 18.24. Microport Scientific Corporation
  • 18.25. Otsuka Medical Devices Co., Ltd.
  • 18.26. Purple MicroPort Cardiovascular Pvt. Ltd
  • 18.27. Sahajanand Medical Technologies Limited
  • 18.28. Stryker Corporation
  • 18.29. Terumo Corporation
  • 18.30. Translumina GmbH
  • 18.31. W. L. Gore & Associates, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL VASCULAR STENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL VASCULAR STENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL VASCULAR STENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL VASCULAR STENT MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL VASCULAR STENT MARKET SIZE, BY MATERIAL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL VASCULAR STENT MARKET SIZE, BY DELIVERY SYSTEM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL VASCULAR STENT MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL VASCULAR STENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL VASCULAR STENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL VASCULAR STENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL VASCULAR STENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES VASCULAR STENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA VASCULAR STENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL VASCULAR STENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL VASCULAR STENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL VASCULAR STENT MARKET SIZE, BY BALLOON-EXPANDABLE STENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL VASCULAR STENT MARKET SIZE, BY BALLOON-EXPANDABLE STENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL VASCULAR STENT MARKET SIZE, BY BALLOON-EXPANDABLE STENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL VASCULAR STENT MARKET SIZE, BY SELF-EXPANDING STENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL VASCULAR STENT MARKET SIZE, BY SELF-EXPANDING STENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL VASCULAR STENT MARKET SIZE, BY SELF-EXPANDING STENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL VASCULAR STENT MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL VASCULAR STENT MARKET SIZE, BY METALLIC STENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL VASCULAR STENT MARKET SIZE, BY METALLIC STENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL VASCULAR STENT MARKET SIZE, BY METALLIC STENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL VASCULAR STENT MARKET SIZE, BY POLYMERIC STENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL VASCULAR STENT MARKET SIZE, BY POLYMERIC STENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL VASCULAR STENT MARKET SIZE, BY POLYMERIC STENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL VASCULAR STENT MARKET SIZE, BY POLYMERIC STENTS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL VASCULAR STENT MARKET SIZE, BY BIODEGRADABLE POLYMERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL VASCULAR STENT MARKET SIZE, BY BIODEGRADABLE POLYMERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL VASCULAR STENT MARKET SIZE, BY BIODEGRADABLE POLYMERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL VASCULAR STENT MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL VASCULAR STENT MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL VASCULAR STENT MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL VASCULAR STENT MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL VASCULAR STENT MARKET SIZE, BY BARE METAL STENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL VASCULAR STENT MARKET SIZE, BY BARE METAL STENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL VASCULAR STENT MARKET SIZE, BY BARE METAL STENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL VASCULAR STENT MARKET SIZE, BY COVERED STENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL VASCULAR STENT MARKET SIZE, BY COVERED STENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL VASCULAR STENT MARKET SIZE, BY COVERED STENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL VASCULAR STENT MARKET SIZE, BY DRUG ELUTING STENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL VASCULAR STENT MARKET SIZE, BY DRUG ELUTING STENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL VASCULAR STENT MARKET SIZE, BY DRUG ELUTING STENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL VASCULAR STENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL VASCULAR STENT MARKET SIZE, BY CORONARY ARTERY DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL VASCULAR STENT MARKET SIZE, BY CORONARY ARTERY DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL VASCULAR STENT MARKET SIZE, BY CORONARY ARTERY DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL VASCULAR STENT MARKET SIZE, BY GASTROINTESTINAL DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL VASCULAR STENT MARKET SIZE, BY GASTROINTESTINAL DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL VASCULAR STENT MARKET SIZE, BY GASTROINTESTINAL DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL VASCULAR STENT MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL VASCULAR STENT MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL VASCULAR STENT MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL VASCULAR STENT MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL VASCULAR STENT MARKET SIZE, BY LOWER EXTREMITIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL VASCULAR STENT MARKET SIZE, BY LOWER EXTREMITIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL VASCULAR STENT MARKET SIZE, BY LOWER EXTREMITIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL VASCULAR STENT MARKET SIZE, BY UPPER EXTREMITIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL VASCULAR STENT MARKET SIZE, BY UPPER EXTREMITIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL VASCULAR STENT MARKET SIZE, BY UPPER EXTREMITIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL VASCULAR STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL VASCULAR STENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL VASCULAR STENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL VASCULAR STENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL VASCULAR STENT MARKET SIZE, BY CARDIAC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL VASCULAR STENT MARKET SIZE, BY CARDIAC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL VASCULAR STENT MARKET SIZE, BY CARDIAC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL VASCULAR STENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL VASCULAR STENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL VASCULAR STENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL VASCULAR STENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. AMERICAS VASCULAR STENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 62. AMERICAS VASCULAR STENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 63. AMERICAS VASCULAR STENT MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 64. AMERICAS VASCULAR STENT MARKET SIZE, BY POLYMERIC STENTS, 2018-2032 (USD MILLION)
  • TABLE 65. AMERICAS VASCULAR STENT MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS VASCULAR STENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS VASCULAR STENT MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS VASCULAR STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 69. NORTH AMERICA VASCULAR STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA VASCULAR STENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 71. NORTH AMERICA VASCULAR STENT MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA VASCULAR STENT MARKET SIZE, BY POLYMERIC STENTS, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA VASCULAR STENT MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA VASCULAR STENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA VASCULAR STENT MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA VASCULAR STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA VASCULAR STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. LATIN AMERICA VASCULAR STENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. LATIN AMERICA VASCULAR STENT MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA VASCULAR STENT MARKET SIZE, BY POLYMERIC STENTS, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA VASCULAR STENT MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 82. LATIN AMERICA VASCULAR STENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA VASCULAR STENT MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA VASCULAR STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA VASCULAR STENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA VASCULAR STENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA VASCULAR STENT MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA VASCULAR STENT MARKET SIZE, BY POLYMERIC STENTS, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE, MIDDLE EAST & AFRICA VASCULAR STENT MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE, MIDDLE EAST & AFRICA VASCULAR STENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA VASCULAR STENT MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA VASCULAR STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE VASCULAR STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE VASCULAR STENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE VASCULAR STENT MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE VASCULAR STENT MARKET SIZE, BY POLYMERIC STENTS, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE VASCULAR STENT MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE VASCULAR STENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE VASCULAR STENT MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE VASCULAR STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. MIDDLE EAST VASCULAR STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. MIDDLE EAST VASCULAR STENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. MIDDLE EAST VASCULAR STENT MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST VASCULAR STENT MARKET SIZE, BY POLYMERIC STENTS, 2018-2032 (USD MILLION)
  • TABLE 105. MIDDLE EAST VASCULAR STENT MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 106. MIDDLE EAST VASCULAR STENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST VASCULAR STENT MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST VASCULAR STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 109. AFRICA VASCULAR STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. AFRICA VASCULAR STENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. AFRICA VASCULAR STENT MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 112. AFRICA VASCULAR STENT MARKET SIZE, BY POLYMERIC STENTS, 2018-2032 (USD MILLION)
  • TABLE 113. AFRICA VASCULAR STENT MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 114. AFRICA VASCULAR STENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA VASCULAR STENT MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA VASCULAR STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC VASCULAR STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC VASCULAR STENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC VASCULAR STENT MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC VASCULAR STENT MARKET SIZE, BY POLYMERIC STENTS, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC VASCULAR STENT MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC VASCULAR STENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC VASCULAR STENT MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC VASCULAR STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL VASCULAR STENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. ASEAN VASCULAR STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. ASEAN VASCULAR STENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. ASEAN VASCULAR STENT MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 129. ASEAN VASCULAR STENT MARKET SIZE, BY POLYMERIC STENTS, 2018-2032 (USD MILLION)
  • TABLE 130. ASEAN VASCULAR STENT MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 131. ASEAN VASCULAR STENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN VASCULAR STENT MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 133. ASEAN VASCULAR STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. GCC VASCULAR STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. GCC VASCULAR STENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. GCC VASCULAR STENT MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 137. GCC VASCULAR STENT MARKET SIZE, BY POLYMERIC STENTS, 2018-2032 (USD MILLION)
  • TABLE 138. GCC VASCULAR STENT MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 139. GCC VASCULAR STENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 140. GCC VASCULAR STENT MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 141. GCC VASCULAR STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPEAN UNION VASCULAR STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPEAN UNION VASCULAR STENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPEAN UNION VASCULAR STENT MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPEAN UNION VASCULAR STENT MARKET SIZE, BY POLYMERIC STENTS, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPEAN UNION VASCULAR STENT MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPEAN UNION VASCULAR STENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPEAN UNION VASCULAR STENT MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION VASCULAR STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. BRICS VASCULAR STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. BRICS VASCULAR STENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. BRICS VASCULAR STENT MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 153. BRICS VASCULAR STENT MARKET SIZE, BY POLYMERIC STENTS, 2018-2032 (USD MILLION)
  • TABLE 154. BRICS VASCULAR STENT MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 155. BRICS VASCULAR STENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS VASCULAR STENT MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 157. BRICS VASCULAR STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. G7 VASCULAR STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. G7 VASCULAR STENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. G7 VASCULAR STENT MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 161. G7 VASCULAR STENT MARKET SIZE, BY POLYMERIC STENTS, 2018-2032 (USD MILLION)
  • TABLE 162. G7 VASCULAR STENT MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 163. G7 VASCULAR STENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 164. G7 VASCULAR STENT MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 165. G7 VASCULAR STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 166. NATO VASCULAR STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 167. NATO VASCULAR STENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. NATO VASCULAR STENT MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 169. NATO VASCULAR STENT MARKET SIZE, BY POLYMERIC STENTS, 2018-2032 (USD MILLION)
  • TABLE 170. NATO VASCULAR STENT MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 171. NATO VASCULAR STENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 172. NATO VASCULAR STENT MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 173. NATO VASCULAR STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL VASCULAR STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. UNITED STATES VASCULAR STENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 176. UNITED STATES VASCULAR STENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. UNITED STATES VASCULAR STENT MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 178. UNITED STATES VASCULAR STENT MARKET SIZE, BY POLYMERIC STENTS, 2018-2032 (USD MILLION)
  • TABLE 179. UNITED STATES VASCULAR STENT MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 180. UNITED STATES VASCULAR STENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 181. UNITED STATES VASCULAR STENT MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 182. UNITED STATES VASCULAR STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 183. CHINA VASCULAR STENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 184. CHINA VASCULAR STENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. CHINA VASCULAR STENT MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 186. CHINA VASCULAR STENT MARKET SIZE, BY POLYMERIC STENTS, 2018-2032 (USD MILLION)
  • TABLE 187. CHINA VASCULAR STENT MARKET SIZE, BY DELIVERY SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 188. CHINA VASCULAR STENT MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 189. CHINA VASCULAR STENT MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 190. CHINA VASCULAR STENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)